1655 related articles for article (PubMed ID: 17324392)
1. PBPK models in risk assessment--A focus on chloroprene.
DeWoskin RS
Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
[TBL] [Abstract][Full Text] [Related]
2. Kinetic modeling of beta-chloroprene metabolism: II. The application of physiologically based modeling for cancer dose response analysis.
Himmelstein MW; Carpenter SC; Evans MV; Hinderliter PM; Kenyon EM
Toxicol Sci; 2004 May; 79(1):28-37. PubMed ID: 14976335
[TBL] [Abstract][Full Text] [Related]
3. Chloroprene: overview of studies under consideration for the development of an IRIS assessment.
Pagan I
Chem Biol Interact; 2007 Mar; 166(1-3):341-51. PubMed ID: 17234169
[TBL] [Abstract][Full Text] [Related]
4. Application of PBPK modeling in support of the derivation of toxicity reference values for 1,1,1-trichloroethane.
Lu Y; Rieth S; Lohitnavy M; Dennison J; El-Masri H; Barton HA; Bruckner J; Yang RS
Regul Toxicol Pharmacol; 2008 Mar; 50(2):249-60. PubMed ID: 18226845
[TBL] [Abstract][Full Text] [Related]
5. Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice.
Marino DJ; Clewell HJ; Gentry PR; Covington TR; Hack CE; David RM; Morgott DA
Regul Toxicol Pharmacol; 2006 Jun; 45(1):44-54. PubMed ID: 16442684
[TBL] [Abstract][Full Text] [Related]
6. Using physiologically-based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl ether acetate.
Kirman CR; Sweeney LM; Corley R; Gargas ML
Risk Anal; 2005 Apr; 25(2):271-84. PubMed ID: 15876203
[TBL] [Abstract][Full Text] [Related]
7. Parameters for pyrethroid insecticide QSAR and PBPK/PD models for human risk assessment.
Knaak JB; Dary CC; Zhang X; Gerlach RW; Tornero-Velez R; Chang DT; Goldsmith R; Blancato JN
Rev Environ Contam Toxicol; 2012; 219():1-114. PubMed ID: 22610175
[TBL] [Abstract][Full Text] [Related]
8. Kinetic modeling of β-chloroprene metabolism: Probabilistic in vitro-in vivo extrapolation of metabolism in the lung, liver and kidneys of mice, rats and humans.
Yang Y; Himmelstein MW; Clewell HJ
Toxicol In Vitro; 2012 Sep; 26(6):1047-55. PubMed ID: 22543297
[TBL] [Abstract][Full Text] [Related]
9. Kinetic modeling of beta-chloroprene metabolism: I. In vitro rates in liver and lung tissue fractions from mice, rats, hamsters, and humans.
Himmelstein MW; Carpenter SC; Hinderliter PM
Toxicol Sci; 2004 May; 79(1):18-27. PubMed ID: 14976339
[TBL] [Abstract][Full Text] [Related]
10. Probabilistic dose-response modeling: case study using dichloromethane PBPK model results.
Marino DJ; Starr TB
Regul Toxicol Pharmacol; 2007 Dec; 49(3):285-300. PubMed ID: 17949874
[TBL] [Abstract][Full Text] [Related]
11. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
Müller L; Gocke E; Lavé T; Pfister T
Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
[TBL] [Abstract][Full Text] [Related]
12. Use of a physiologically based model to predict systemic uptake and respiratory elimination of perchloroethylene.
Dallas CE; Muralidhara S; Chen XM; Ramanathan R; Varkonyi P; Gallo JM; Bruckner JV
Toxicol Appl Pharmacol; 1994 Sep; 128(1):60-8. PubMed ID: 8079355
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of
Clewell HJ; Campbell JL; Van Landingham C; Franzen A; Yoon M; Dodd DE; Andersen ME; Gentry PR
Inhal Toxicol; 2019; 31(13-14):468-483. PubMed ID: 31992090
[No Abstract] [Full Text] [Related]
14. Determination of age and gender differences in biochemical processes affecting the disposition of 2-butoxyethanol and its metabolites in mice and rats to improve PBPK modeling.
Corley RA; Grant DM; Farris E; Weitz KK; Soelberg JJ; Thrall KD; Poet TS
Toxicol Lett; 2005 Mar; 156(1):127-61. PubMed ID: 15705493
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based pharmacokinetic modeling of a ternary mixture of alkyl benzenes in rats and humans.
Tardif R; Charest-Tardif G; Brodeur J; Krishnan K
Toxicol Appl Pharmacol; 1997 May; 144(1):120-34. PubMed ID: 9169076
[TBL] [Abstract][Full Text] [Related]
16. Physiologically-based pharmacokinetic and toxicokinetic models in cancer risk assessment.
Krishnan K; Johanson G
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2005; 23(1):31-53. PubMed ID: 16291521
[TBL] [Abstract][Full Text] [Related]
17. Steady-state solutions to PBPK models and their applications to risk assessment I: Route-to-route extrapolation of volatile chemicals.
Chiu WA; White P
Risk Anal; 2006 Jun; 26(3):769-80. PubMed ID: 16834633
[TBL] [Abstract][Full Text] [Related]
18. Update of potency factors for asbestos-related lung cancer and mesothelioma.
Berman DW; Crump KS
Crit Rev Toxicol; 2008; 38 Suppl 1():1-47. PubMed ID: 18671157
[TBL] [Abstract][Full Text] [Related]
19. Application of a physiologically based pharmacokinetic model for reference dose and reference concentration estimation for acetone.
Gentry PR; Covington TR; Clewell HJ; Anderson ME
J Toxicol Environ Health A; 2003 Dec; 66(23):2209-25. PubMed ID: 14612334
[TBL] [Abstract][Full Text] [Related]
20. Use of in vitro data for construction of a physiologically based pharmacokinetic model for naphthalene in rats and mice to probe species differences.
Quick DJ; Shuler ML
Biotechnol Prog; 1999; 15(3):540-55. PubMed ID: 10356275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
